Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.

Roselle A HerringFariba Shojaee-MoradieRobert GaresseMary StevenageNicola JacksonBarbara A FieldingAgampodi MendisSigurd JohnsenA Margot UmplebyMelanie DaviesDavid L Russell-Jones

Published in: Diabetes care (2020)

During insulin withdrawal, the increase in BOHB with dapagliflozin may be partially due to increased lipolysis. However, reduced renal excretion, reduced BOHB uptake by peripheral tissues, or a metabolic switch to increased ketogenesis within the liver may also play a role.

Keyphrases

type diabetes
glycemic control
liver failure
adipose tissue
gene expression
respiratory failure
drug induced
aortic dissection
insulin resistance
metabolic syndrome
skeletal muscle
acute respiratory distress syndrome